Home » Stocks » Trinity Biotech

Trinity Biotech PLC (TRIB)

Stock Price: $2.49 USD -0.13 (-4.96%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed
After-hours: $2.53 +0.04 (1.61%) Jul 31, 7:25 PM

Stock Price Chart

Key Info

Market Cap 51.06M
Revenue (ttm) 89.59M
Net Income (ttm) -28.91M
Shares Out 20.90M
EPS (ttm) -1.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 31, 2020
Last Price $2.49
Previous Close $2.62
Change ($) -0.13
Change (%) -4.96%
Day's Open 2.60
Day's Range 2.43 - 2.61
Day's Volume 964,354
52-Week Range 0.56 - 3.28

More Stats

Market Cap 51.06M
Enterprise Value 136.83M
Earnings Date (est) Oct 22, 2020
Ex-Dividend Date n/a
Shares Outstanding 20.90M
Float 14.43M
EPS (basic) -1.4
EPS (diluted) -1.48
FCF / Share -0.25
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 660,706
Short Ratio 0.57
Short % of Float n/a
Beta 1.74
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.57
PB Ratio 82.01
Revenue 89.59M
Operating Income -24.11M
Net Income -28.91M
Free Cash Flow -5.98M
Net Cash -85.77M
Net Cash / Share -4.18
Gross Margin 42.55%
Operating Margin -26.91%
Profit Margin -32.00%
FCF Margin -6.67%
ROA 2.35%
ROE -137.64%
ROIC -16.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.00*
Low
4.00
Current: $2.49
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue90.4497.0499.1499.6110010591.2282.5177.9589.64
Revenue Growth-6.8%-2.12%-0.47%-0.58%-4.46%14.97%10.55%5.85%-13.04%-
Gross Profit38.1241.4541.8943.4846.5149.3845.2242.2540.1343.95
Operating Income-24.11-20.23-37.67-39.8513.5115.449.0017.1715.7860.50
Net Income-28.91-22.09-40.27-10121.8017.219.6517.3415.5960.42
Shares Outstanding96.1696.1696.1695.8494.3192.3088.9985.3284.1282.95
Earnings Per Share-1.40-1.04-1.88-4.400.480.720.400.760.722.80
EPS Growth-----33.33%80%-47.37%5.56%-74.29%-
Dividend Per Share----0.220.220.200.150.10-
Dividend Growth----0%10%33.33%50%--
Operating Cash Flow5.885.989.3710.5613.5215.698.7718.8218.7722.97
Capital Expenditures-11.85-17.39-15.07-20.76-26.59-27.76-23.18-15.30-9.24-9.00
Free Cash Flow-5.98-11.41-5.70-10.21-13.07-12.07-14.413.539.5413.97
Cash & Equivalents16.4030.2857.6177.111029.1022.3274.9571.0958.00
Total Debt10282.3493.8493.2492.83---0.110.27
Net Cash / Debt-85.77-52.07-36.23-16.139.139.1022.3274.9570.9857.73
Assets131152193250364243226197171161
Liabilities12610812814115045.8743.4828.0320.1719.59
Book Value4.7144.0565.20109214197183169151141
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Trinity Biotech PLC
Country Ireland
Employees 579
CEO Ronan O'Caoimh

Stock Information

Ticker Symbol TRIB
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: TRIB

Description

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.